Inhibitors in haemophilia patients

• References

• 1 Astermark J. Genetic and environmental risk factors for FVIII inhibitor development. J Thromb Haemost 2007; 5 (Suppl. 02) SYM-M-029.
• 2 Austen DEG, Lechner K, Rizza CR. et al. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 1982; 47: 72-75.
• 3 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
• 4 Goudemand J, Rothschild C, Demiguel V. et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
• 5 Oldenburg J, Picard JK, Schwaab R. et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
• 6 Santagostino E. Can the genetic profile predict inhibitor development in hemophilia A. J Thromb Haemost 2007; 5: 261-262.
• 7 Santagostino E, Mancuso ME, Rocino A. et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.
• 8 Schramm W, Krebs H. HIV infection and causes of death in patients with hemophilia in Germany. In: Scharrer I, Schramm W. 37th Hemophilia Symposium Hamburg 2006. Berlin Heidelberg: Springer; 2008: 5-16.
• 9 Schwaab R, Brackmann H-H, Meyer C. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
• 10 Serban M, Schramm W. Hemostazeologie clinica. Timisoara: Brumar 2001; 221.